Abstract
CCL21 promotes immune activity in the tumor microenvironment (TME) by colocalizing dendritic cells (DC) and T cells programing ectopic lymph node architectural structures that correlate with cancer prognosis. Innovative strategies to deliver CCL21 in cancer patients will reactivate the downregulated immune activity in the TME. Immune escape mechanisms are upregulated in the TME that promote tumor immune evasion. CCL21 combined with inhibition of dominant pathways of immune evasion will aid in the development of effective immunotherapy for cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE et al (2017) Phase I trial of intratumoral injection of CCL21 gene-modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8(+) T-cell infiltration. Clin Cancer Res 23(16):4556–4568
Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263–274
Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED et al (2000) Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6:1755–1766
Johnson SK, Kerr KM, Chapman AD, Kennedy MM, King G, Cockburn JS et al (2000) Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer 27:27–35
Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y et al (2006) Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 94:275–280
Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V et al (2008) Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 26:4410–4417
Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX et al (2000) Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 164:4558–4563
Sharma S, Stolina M, Zhu L, Lin Y, Batra R, Huang M et al (2001) Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 61:6406–6412
Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M et al (2004) Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 10:2891–2901
Yang SC, Batra RK, Hillinger S, Reckamp KL, Strieter RM, Dubinett SM et al (2006) Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 66:3205–3213
Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD (1998) Williams LT. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci U S A 95:258–263
Friedman RS, Jacobelli J, Krummel MF (2006) Surface-bound chemokines capture and prime T cells for synapse formation. Nat Immunol 7:1101–1108. Epub 2006 Sept 10
Flanagan K, Moroziewicz D, Kwak H, Horig H, Kaufman HL (2004) The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4+ T cells. Cell Immunol 231:75–84. Epub 2005 Jan 21
Sharma S, Miller P, Stolina M, Zhu L, Huang M, Paul R et al (1997) Multi-component gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with Interleukin 7/Herpes Simplex Thymidine Kinase-transduced autologous tumor and ex vivo-activated dendritic cells. Gene Therapy 4:1361–1370
Miller PW, Sharma S, Stolina M, Butterfield LH, Luo J, Lin Y et al (2000) Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum Gene Ther 11:53–65
Sharma S, Stolina M, Yang SC, Baratelli F, Lin JF, Atianzar K et al (2003) Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 9:961–968
Kirk CJ, Hartigan-O’Connor D, Mule JJ (2001) The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res 61:8794–8802
Novak L, Igoucheva O, Cho S, Alexeev V (2007) Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Mol Cancer Ther 6:1755–1764
Liang CM, Zhong CP, Sun RX, Liu BB, Huang C, Qin J et al (2007) Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity. J Virol 81:9502–9511. Epub 2007 Jun 13
Wu S, Xing W, Peng J, Yuan X, Zhao X, Lei P et al (2008) Tumor transfected with CCL21 enhanced reactivity and apoptosis resistance of human monocyte-derived dendritic cells. Immunobiology 213:417–426. Epub 2007 Nov 28
Yousefieh N, Hahto SM, Stephens AL, Ciavarra RP (2009) Regulated expression of CCL21 in the prostate tumor microenvironment inhibits tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Microenviron 2(1):59–67
Hall B, Andreeff M, Marini F (2007) The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb Exp Pharmacol 180:263–283
Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M (2002) Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62:3603–3608
Tatsumi T, Huang J, Gooding WE, Gambotto A, Robbins PD, Vujanovic NL et al (2003) Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res 63:6378–6386
Lapteva N, Aldrich M, Rollins L, Ren W, Goltsova T, Chen SY et al (2009) Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther 17:1626–1636. Epub 2009 Jun 16
Coppola D, Mule JJ (2008) Ectopic lymph nodes within human solid tumors. J Clin Oncol 26:4369–4370
Kirk CJ, Hartigan-O’Connor D, Nickoloff BJ, Chamberlain JS, Giedlin M, Aukerman L et al (2001) T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 61:2062–2070
Peske JD, Thompson ED, Gemta L, Baylis RA, Fu YX, Engelhard VH (2015) Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nature Commun 6:7114
Baratelli F, Takedatsu H, Hazra S, Peebles K, Luo J, Kurimoto PS et al (2008) Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer. J Transl Med 6:38
Huebsch N, Mooney DJ (2009) Inspiration and application in the evolution of biomaterials. Nature 462:426–432
Li WA, Mooney DJ (2013) Materials based tumor immunotherapy vaccines. Curr Opin Immunol 25:238–245
Hu D, Lau OD, Wang L, Wang G, Schaue D, Zhu L et al (2012) A novel modular polymer platform for the treatment of head and neck squamous cell carcinoma in an animal model. Arch Otolaryngol Head Neck Surg 138:412–417
Lin Y, Luo J, Zhu WE, Srivastava M, Schaue D, Elashoff DA et al (2014) A cytokine-delivering polymer is effective in reducing tumor burden in a head and neck squamous cell carcinoma murine model. Otolaryngol Head Neck Surg 151:447–453
Ross DA, Hundal JS, Son YH, Ariyan S, Shin J, Lowlicht R et al (2004) Microsurgical free flap reconstruction outcomes in head and neck cancer patients after surgical extirpation and intraoperative brachytherapy. Laryngoscope 114:1170–1176
Ali OA, Huebsch N, Cao L, Dranoff G, Mooney DJ (2009) Infection-mimicking materials to program dendritic cells in situ. Nat Mater 8:151–158
Kar UK, Srivastava MK, Andersson A, Baratelli F, Huang M, Kickhoefer VA et al (2011) Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. PLoS One 6:e18758
Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA et al (2015) Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348:803–808
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563–567
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465
Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA et al (2015) Overall survival and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33(18):2004–2012
Soria JC, Marabelle A, Brahmer JR, Gettinger S (2015) Immune checkpoint modulation for non-small cell lung cancer. Clin Cancer Res 21:2256–2262
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568–571
Delamarre L, Mellman I, Yadav M (2015) Cancer immunotherapy. Neo approaches to cancer vaccines. Science 348:760–761
Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M et al (2014) Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 94:107–116
Salehi-Rad R, Walser T, So S, Park S, Sharma L, Jay SD (2017) CCL21 combined with PD-1 blockade cooperatively inhibits tumor growth in KRAS murine model of NSCLC. J Thorac Oncol 12:S1537
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Sharma, S., Kadam, P., Dubinett, S. (2020). CCL21 Programs Immune Activity in Tumor Microenvironment. In: Birbrair, A. (eds) Tumor Microenvironment. Advances in Experimental Medicine and Biology, vol 1231. Springer, Cham. https://doi.org/10.1007/978-3-030-36667-4_7
Download citation
DOI: https://doi.org/10.1007/978-3-030-36667-4_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-36666-7
Online ISBN: 978-3-030-36667-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)